Rx0000160 |
Incyte Corporation |
09/30/2022 |
50881001060 |
Jakafi Oral Tablet 10 mg 60 Pack |
07/01/2022 |
311.54 |
16200.00 |
06/12/2028 |
Single Source Drug |
None |
1 |
Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000160 |
Incyte Corporation |
09/30/2022 |
50881001560 |
Jakafi Oral Tablet 15 mg 60 Pack |
07/01/2022 |
311.54 |
16200.00 |
06/12/2028 |
Single Source Drug |
None |
1 |
Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000160 |
Incyte Corporation |
09/30/2022 |
50881002060 |
Jakafi Oral Tablet 20 mg 60 Pack |
07/01/2022 |
311.54 |
16200.00 |
06/12/2028 |
Single Source Drug |
None |
1 |
Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000160 |
Incyte Corporation |
09/30/2022 |
50881002560 |
Jakafi Oral Tablet 25 mg 60 Pack |
07/01/2022 |
311.54 |
16200.00 |
06/12/2028 |
Single Source Drug |
None |
1 |
Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000160 |
Incyte Corporation |
09/30/2022 |
50881000560 |
Jakafi Oral Tablet 5 mg 60 Pack |
07/01/2022 |
311.54 |
16200.00 |
06/12/2028 |
Single Source Drug |
None |
1 |
Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000040 |
Ingenus Pharmaceuticals, LLC |
06/30/2022 |
50742051330 |
Nitro-Dur Patch 0.1mg/hr 30 ct |
04/11/2022 |
182.26 |
702.99 |
None |
Single Source Drug |
520 |
None |
Increased API, overhead, expenses, and distribution costs causing need for price increase |
None |
No changes made |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000040 |
Ingenus Pharmaceuticals, LLC |
06/30/2022 |
50742051430 |
Nitro-Dur Patch 0.2mg/hr 30 ct |
04/11/2022 |
196.09 |
756.35 |
None |
Single Source Drug |
398 |
None |
Increased API, overhead, expenses, and distribution costs causing need for price increase |
None |
No changes made |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000040 |
Ingenus Pharmaceuticals, LLC |
06/30/2022 |
50742051530 |
Nitro-Dur Patch 0.3mg/hr 30 ct |
04/11/2022 |
412.15 |
1589.73 |
None |
Single Source Drug |
5100 |
None |
Increased API, overhead, expenses, and distribution costs causing need for price increase |
None |
No changes made |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000040 |
Ingenus Pharmaceuticals, LLC |
06/30/2022 |
50742051630 |
Nitro-Dur Patch 0.4mg/hr 30 ct |
04/11/2022 |
219.81 |
847.85 |
None |
Single Source Drug |
284 |
None |
Increased API, overhead, expenses, and distribution costs causing need for price increase |
None |
No changes made |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000040 |
Ingenus Pharmaceuticals, LLC |
06/30/2022 |
50742051730 |
Nitro-Dur Patch 0.6mg/hr 30 ct |
04/11/2022 |
238.40 |
919.53 |
None |
Single Source Drug |
291 |
None |
Increased API, overhead, expenses, and distribution costs causing need for price increase |
None |
No changes made |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000040 |
Ingenus Pharmaceuticals, LLC |
06/30/2022 |
50742051830 |
Nitro-Dur Patch 0.8mg/hr 30 ct |
04/11/2022 |
446.99 |
1724.12 |
None |
Single Source Drug |
1908 |
None |
Increased API, overhead, expenses, and distribution costs causing need for price increase |
None |
No changes made |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000287 |
Insmed Incorporated |
03/31/2022 |
71558059028 |
AMIKACIN LIPOSOME INHALATION SUSPENSION EQ 590MG BASE/8.4ML (28 Vials) |
01/01/2022 |
990.53 |
13372.21 |
05/15/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product developed in-house |
Rx0000266 |
Intercept Pharmaceuticals, Inc. |
03/31/2022 |
69516001030 |
Ocaliva (obeticholic acid) tablets 10mg 30ct |
01/20/2022 |
448.18 |
8044.51 |
05/27/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000266 |
Intercept Pharmaceuticals, Inc. |
03/31/2022 |
69516000530 |
Ocaliva (obeticholic acid) tablets 5mg 30ct |
01/20/2022 |
448.18 |
8044.51 |
05/27/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2022 |
15054104005 |
Drug product name: Increlex. Drug product strength: 10 mg/ml. Drug product dosage form: vial. Drug product package size: 4ml. |
01/01/2022 |
502.00 |
5629.00 |
03/11/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
The product was not acquired by Ipsen within the previous five years. |
Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2022 |
15054004301 |
Drug product name: Onivyde. Drug product strength: 43 mg/10 ml (4.3 mg/ml). Drug product dosage form: vial. Drug product package size: 10ml. |
01/01/2022 |
111.00 |
2583.00 |
10/15/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/03/2017 |
Merrimack Pharmaceuticals |
None |
1 |
For purposes of 22 CCR § 96070(b)(12)(c) (requirement to report the purchase price of the relevant drug, if the drug was acquired by the manufacturer within the previous five years), Ipsen purchased the global oncology assets of Merrimack Pharmaceuticals in April 2017, including Onivyde. The purchase price of the drug product (as Ipsen understands that data element) is not in the public domain or otherwise publicly available. However, information regarding Ipsen’s purchase of the assets from Merrimack Pharmaceuticals is available on p. 97, Note 12.1.1 of section 3.2.5, of the Registration Document located at: https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/2018/03/15164935/IPSEN_DDR_2017_VA_complet_clean-003.pdf |
1652.40 |
None |
2015 |
1620.00 |
None |
The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The information provided in response to 22 CCR § 96070(b)(11) contains price increases for the drug product when the NDC for the product was 69171-0398-01 |
Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2022 |
15054112004 |
Drug product name: Somatuline Depot - New NDC. Drug product strength: 120 mg/0.5 ml. Drug product dosage form: syringe. Drug product package size: .50 ml. |
01/01/2022 |
412.00 |
9562.00 |
03/08/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This NDC was launched on September 1, 2019 and will replace NDC 15054112003. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. |
Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2022 |
15054106004 |
Drug product name: Somatuline Depot - New NDC. Drug product strength: 60 mg/0.2 ml. Drug product dosage form: syringe. Drug product package size: .20 ml. |
01/01/2022 |
262.00 |
6088.00 |
03/08/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This NDC was launched on September 1, 2019 and will replace NDC 15054106003. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. |
Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2022 |
15054109004 |
Drug product name: Somatuline Depot - New NDC. Drug product strength: 90 mg/0.3 ml. Drug product dosage form: syringe. Drug product package size: .30 ml. |
01/01/2022 |
349.00 |
8108.00 |
03/08/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This NDC was launched on September 1, 2019 and will replace NDC 15054109003. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. |
Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2022 |
15054112003 |
Drug product name: Somatuline Depot - Old NDC. Drug product strength: 120 mg/0.5 ml. Drug product dosage form: syringe. Drug product package size: .50 ml. |
01/01/2022 |
412.00 |
9562.00 |
03/08/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
The product was not acquired by Ipsen within the previous five years. |
Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2022 |
15054109003 |
Drug product name: Somatuline Depot - Old NDC. Drug product strength: 90 mg/0.3 ml. Drug product dosage form: syringe. Drug product package size: .30 ml. |
01/01/2022 |
349.00 |
8108.00 |
03/08/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
The product was not acquired by Ipsen within the previous five years. |
Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2022 |
15054106003 |
Drug product name: Somatuline Depot - Old NDC. Drug product strength: 60 mg/0.2 ml. Drug product dosage form: syringe. Drug product package size: .20 ml. |
01/01/2022 |
262.00 |
6088.00 |
03/08/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
The product was not acquired by Ipsen within the previous five years. |